Navigation Links
Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
Date:5/19/2008

CHICAGO (May 19, 2008) New research published in the Journal of the American College of Surgeons shows long-term survival and liver rejection rates are equivalent for African-American liver transplant patients as compared with patients of other races. The study also suggests that although other factors such as liver cancer or hepatitis may negatively influence long-term survival, race does not.

Racial disparities in incidence, severity, methods of treatment and access to care have previously been shown in a variety of diseases, including liver disease. African-American patients appear to be underrepresented among liver transplantation recipients. In 2005, for instance, only 6.8 percent of all patients in the United Network for Organ Sharing database and 9.4 percent of liver transplant recipients were African American, compared with the general population of the United States, in which African Americans represented 12.9 percent of the total.

Survival rates after liver transplantation have been shown to be influenced by race, but earlier data on this subject has been conflicting and may not reflect current management of liver transplant recipients, says Dr. Johnny C. Hong, assistant professor of surgery, Department of Surgery and Liver and Pancreas Transplantation at the University of California, Los Angeles Medical Center in Los Angeles, California. Although our study is the first to find equivalent long-term outcomes among racial groups after liver transplantation, access to care for all patients with end-stage liver disease clearly remains a major goal for all transplant centers. Like many diseases, our patients are best served with early involvement of a multidisciplinary team.

Liver transplantation is required for patients with severe (end-stage) liver disease. People who have liver transplants require close monitoring after their operation and must take drugs that prevent rejection of the transplanted organ (immunosuppressants) for the rest of their lives.

Using information from the UCLA transplant database, researchers reviewed 2,728 patients who underwent primary liver transplantation at the Dumont-UCLA Transplant Center from 1984 to 2007. Among these patients, 57 percent were Caucasian, 28 percent were Hispanic, 11 percent were Asian and 4 percent were African American.

Results were analyzed during two time periods correlating to the primary immunosuppressant drug used during that era (cyclosporine from 1984-1993 and tacrolimus from 1994-2007). The use of the modern immunosuppressant drug tacrolimus substantially reduced the risk of acute rejection, graft loss and patient death compared with cyclosporine and resulted in a marked improvement of patient and graft survival outcomes in African-American patients after liver transplantation. Statistically significant independent predictors of diminished survival in liver transplant patients were older age ( > 55 years), cryptogenic cirrhosis (scarring of the liver), liver cancer and hepatitis C cirrhosis. Race was not found to be a predictor of survival.


'/>"/>

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
2. JAMA publication features study on depression and head and neck cancer
3. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
4. With age comes a sense of peace and calm, population research center study shows
5. Study: Doctors Significantly Less Likely to Provide Women with Treatments to Prevent Heart Attacks
6. Study finds 21st birthday binge drinking extremely common; can pose serious health hazards
7. Study Finds Gender Disparity in Community-Acquired Pneumonia
8. Cellvizio(R) Confocal Microscopy Improves ERCP Bile Duct Cancer Detection, According to New Study Presented at DDW
9. Not All Colon Cancer Patients Need Chemotherapy: Study
10. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
11. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
(Date:2/23/2017)... ... 2017 , ... On February 22, 2017 the U.S. Department ... withdraw previous guidance issued by the Obama Administration requiring schools to treat transgender ... by the Obama Administration came in response to a growing number of states ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/23/2017)... -- Visiomed, the French leader in medical grade ... the landscape of healthcare with their innovative use ... solutions. Recognizing the rising demand of self-monitoring alongside ... walls, Visiomed has launched BewellConnect, the most ground-breaking ... that is empowering the lives of patients. ...
(Date:2/23/2017)... , Feb. 23, 2017 ITL Limited, ( ASX: ITD ... results for the half year ended 31 December 2016 compared with ... Update" presentation can be viewed here . ... 2015: $1.04m; up 104%) Earnings per share of ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
Breaking Medicine Technology: